Investors in ADVR should be excited about the first public forum that ADVR is
presenting since 2 years ago. (The American Society of Microbiology) The Barbados
preliminary results are very convincing and yet no one seems to have put 2 and 2
together to realize that the final results are being presented in 1 week. Don't say that I
didn't alert you to the opportunity to buy at $.36
The last time that ADVR had any media coverage, the stock went from $.30 to $1.90
in 3 days on 12,000,000 shares daily volume.
Since 2 years ago, this company has obtained respected research scientists from Mt.
Sinai Med. Center among others, has hired numerous PhD's, has attracted the interest
of the National Cancer Institute (NCI) which has recently renewed its research
agreement to study ADVR's flagship drug, RETICULOSE, and has obtained approval
from the Argentinian FDA for Phase 3 human clinical trials for AIDS and Human
Papilloma Virus (HPV, Genital Warts).
For those of you who would like to reference the preliminary results of the Reticulose
study, you can link to the following:
pslgroup.com
For those of you who would like to reference the article from the Journal of
Investigative Medicine as reported in Infectious Disease News, which prompted the
stock price jump from $.30 to $1.90, you can link to the following:
slackinc.com
Frankly, the report to be presented at the upcoming Microbiology Society Conference
on May 21, is much more impressive and significant.
Those of you with access to Silicon Investor, please feel free to re-post on your thread.
POP 6 |
